Memorial Sloan Kettering Cancer Center: Myelodysplastic Syndromes trials

The registry lists 50 Myelodysplastic Syndromes studies with Memorial Sloan Kettering Cancer Center as lead sponsor. 1 are open to participants now and 24 have results posted.

Phase 1 12Phase 2 32Phase 3 1Phase 4 1No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Cord Blood Transplantation in Children and Young Adults With Blood CancerRecruitingNCT07566377Phase 2
• A Study of E7820 in People With Bone Marrow (Myeloid) CancersCompletedNCT05024994Phase 2Results posted
• A Study of the Effect of Blood Stem Cell Transplant After Chemotherapy Alone in Patients With Fanconi AnemiaTerminatedNCT03600909Phase 2Results posted
• Tocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood TransplantationCompletedNCT03434730Phase 2Results posted
• GVHD Prophylaxis With Post Transplant Cyclophosphamide for Patients With Renal Insufficiency Undergoing a Conventional 8/8 HLA-matched Related or Unrelated Donor Allogeneic Hematopoietic Stem Cell TransplantTerminatedNCT02360111Not applicableResults posted
• Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) in Patients With Myelodysplastic SyndromesCompletedNCT02228525Phase 2Results posted
• Maintenance Low Dose 5'-Azacitidine Post T Cell Depleted Allogeneic Stem Cell Transplantation for Patients With Myelodysplastic Syndrome and Acute Myelogenous Leukemia With High Risk for Post-Transplant RelapseCompletedNCT01995578Phase 2Results posted
• Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological MalignanciesCompletedNCT01682226Phase 2Results posted
• Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible DonorTerminatedNCT01598025Not applicableResults posted
• Posaconazole Versus Micafungin for Prophylaxis Against Invasive Fungal Infections During Neutropenia in Patients Undergoing Chemotherapy for Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia or Myelodysplastic SyndromeCompletedNCT01200355Phase 4Results posted
• HLA-Compatible Related or Unrelated Donors With CD34+ Enriched, T-cell Depleted Peripheral Blood Stem Cells Isolated by the CliniMACS System in the Treatment of Patients With Hematologic MalignanciesCompletedNCT01119066Phase 2Results posted
• Does Maitake Mushroom Extract Enhance Hematopoiesis in Myelodysplastic Patients?CompletedNCT01099917Phase 2Results posted
• Hematopoietic Stem Cell Transplantation for the Treatment of Patients With Fanconi Anemia Lacking a Genotypically Identical Donor, Using a Chemotherapy Only Cytoreduction With Busulfan, Cyclophosphamide and FludarabineCompletedNCT00987480Phase 2Results posted
• Conditioning Regimen and the Transplantation of Unrelated Donor Umbilical Cord Blood in Patients With Hematologic Malignancies.CompletedNCT00739141Phase 2Results posted
• Rituximab (Rituxan) for the Prevention of EBV-LPD Epstein Barr Virus (EBV) Lymphoproliferative Disorder Post T Cell Depleted Unrelated and HLA Mis-matched Related HSCTCompletedNCT00648037Not applicableResults posted
• Busulfan, Melphalan, and Fludarabine With Peri-transplant Palifermin, Followed by a T-Cell Depleted Hematopoietic Stem Cell Transplant From HLA Matched or Mismatched Related or Unrelated Donors in Patients With Advanced Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML)CompletedNCT00629798Phase 2Results posted
• A Myeloablative Conditioning Regimen and Total Body Irradiation Followed by the Transplantation for Patients With Hematological MalignancyCompletedNCT00597519Phase 2Results posted
• Trial of Allogeneic Stem Cell Transplants From HLA Compatible, Related and Unrelated Donors After a Myeloablative Preparative Regimen With Hyperfractionated TBI, Thiotepa and Fludarabine For Adult Patients With Lymphohematopoietic DisordersCompletedNCT00587054Phase 2Results posted
• Phase II Trial of a Chemotherapy Alone Regimen of IV Busulfan (Busulfex), Melphalan and Fludarabine as Myeloablative Regimen Followed by an Allogeneic T-Cell Depleted Hematopoietic Stem Cell Transplant From an HLA-Identical, or HLA-Non Identical Related or Unrelated DonorCompletedNCT00582933Phase 2Results posted
• Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell TransplantCompletedNCT00526292Phase 2Results posted
• Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other DiseaseCompletedNCT00423514Phase 1/2Results posted
• Vaccine Therapy and GM-CSF in Treating Patients With Acute Myeloid Leukemia, Myelodysplastic Syndromes, Non-Small Cell Lung Cancer, or MesotheliomaCompletedNCT00398138Phase 1Results posted
• Decitabine and Tretinoin in Treating Patients With Myelodysplastic SyndromesCompletedNCT00382200Phase 1/2Results posted
• Melphalan, Fludarabine, and Alemtuzumab Followed by Peripheral Stem Cell Transplant in Treating Patients With Hematologic CancerCompletedNCT00027560Phase 2Results posted
• Chemotherapy and Monoclonal Antibody Therapy in Treating Patients With Advanced Myeloid CancerCompletedNCT00014495Phase 1/2Results posted
• Cord Blood Transplant in Adults With Blood CancersActive, not recruitingNCT05884333Phase 2
• A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow TransplantActive, not recruitingNCT04872595Phase 2
• Study of a Geriatric Assessment to Plan a Treatment Approach for Older People With Various Blood DisordersActive, not recruitingNCT04761770Phase 2
• Feasibility and Safety of Functional Performance Testing in Patients Undergoing Hematopoietic Cell TransplantationCompletedNCT02598752
• Palifermin With Leuprolide Acetate for the Promotion of Immune Recovery Following Total Body Irradiation Based T-Cell Depleted Allogeneic Hematopoietic Stem Cell TransplantationActive, not recruitingNCT01746849Phase 2
• Targeted Atomic Nano-Generators (Actinium-225-Labeled Humanized Anti-CD33 Monoclonal Antibody HuM195) in Patients With Advanced Myeloid MalignanciesCompletedNCT00672165Phase 1
• Dose Escalation Trial of WT1-Sensitized T Cells for Residual or Relapsed Leukemia After Allogeneic Hematopoietic Progenitor Cell TransplantationCompletedNCT00620633Phase 1
• Structural Imaging and Cognitive Functions in Adult Stem Cell Transplant Recipients Treated With Chemotherapy Alone or in Combination With RadiotherapyCompletedNCT00606216
• Abdominal Obesity and Cardiovascular Risk Factors in Women Who Survived Cancer or a Related Illness Following Total Body Irradiation and Stem Cell TransplantCompletedNCT00510315
• Pyroxamide in Treating Patients With Advanced CancerCompletedNCT00042900Phase 1
• FR901228 in Treating Patients With Myelodysplastic Syndrome, Acute Myeloid Leukemia, or Non-Hodgkin's LymphomaCompletedNCT00042822Phase 2
• Total-Body Irradiation and Chemotherapy Followed By Donor Bone Marrow Transplant in Treating Young Patients With Hematologic CancerCompletedNCT00028730Phase 2
• Music Therapy to Ease Pain and Emotional Distress in Patients With Hematologic Cancer Who Are Undergoing High-Dose Therapy and Stem Cell TransplantationCompletedNCT00014482Not applicable
• Combination Chemotherapy Followed by Bone Marrow Transplantation in Treating Patients With Advanced Hematologic CancerCompletedNCT00014469Phase 2
• PS-341 in Treating Patients With Hematologic CancerCompletedNCT00006098Phase 1
• Radiolabeled Monoclonal Antibody Therapy and Etoposide Followed by Peripheral Stem Cell Transplantation in Treating Patients With Advanced Myelodysplastic Syndrome or Refractory LeukemiaCompletedNCT00006040Phase 1
• Phenylbutyrate Plus Azacitidine in Treating Patients With Acute Myeloid Leukemia, Myelodysplasia, Non-Hodgkin's Lymphoma, Multiple Myeloma, Non-small Cell Lung Cancer, or Prostate CancerCompletedNCT00006019Phase 2
• St. John's Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for CancerCompletedNCT00005805Phase 3
• Sodium Salicylate in Treating Patients With Advanced Myelodysplastic Syndrome, Acute Myelogenous Leukemia, or Chronic Lymphocytic LeukemiaCompletedNCT00004245Phase 1
• Vaccine Therapy in Treating Patients With Myelodysplastic SyndromeCompletedNCT00003959Phase 1
• Decitabine in Treating Patients With Myelodysplastic SyndromeCompletedNCT00003361Phase 2
• Monoclonal Antibody Therapy in Treating Patients With Myelodysplastic Syndrome or Relapsed or Refractory Acute Myeloid Leukemia or Chronic Myelogenous LeukemiaCompletedNCT00002890Phase 1
• Chemotherapy in Treating Patients With Newly Diagnosed Acute or Chronic Myelogenous Leukemia or Myelodysplastic SyndromeCompletedNCT00002800Phase 2
• T-cell Depleted Bone Marrow and G-CSF Stimulated Peripheral Stem Cell Transplantation From Related Donors in Treating Patients With Leukemia, Lymphoblastic Lymphoma, Myelodysplastic Syndrome, or Aplastic AnemiaCompletedNCT00002718Phase 2
• Combination Chemotherapy and Bone Marrow Transplantation in Treating Patients With Leukemia or Myelodysplastic SyndromeCompletedNCT00002502Phase 2